NCT06724640View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

PHASE1RecruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

August 16, 2028

Study Completion Date

August 16, 2028

Conditions
HIV Infections
Interventions
DRUG

VH4011499 Injection

VH4011499 Injection will be administered either subcutaneously or intramuscularly.

DRUG

Placebo for VH4011499 Injection

Placebo for VH4011499 Injection will be administered either subcutaneously or intramuscularly.

Trial Locations (1)

89113

RECRUITING

GSK Investigational Site, Las Vegas

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY

NCT06724640 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV | Biotech Hunter | Biotech Hunter